What is the current stock price of ALK-Abelló A/S (AKBLF)?

As of the latest market data, ALK-Abelló A/S (AKBLF) is trading at $31.35. The stock has seen a loss of 0.00% today.

Does ALK-Abelló A/S (AKBLF) pay a dividend?

Based on current data, ALK-Abelló A/S does not have a confirmed active dividend policy.

What is the market cap of ALK-Abelló A/S?

The current market capitalization of ALK-Abelló A/S (AKBLF) is approximately unavailable.

AKBLF

ALK-Abelló A/S·Healthcare

31.35

0.000%(+0.00)

Market Closed

34.95

11.483%(+3.60)

After Hours

Last Updated: — ET

52W L: $19.9052W H: $36.14

AKBLF NEWS

seekingalpha.com

Mar 16

ALK-Abelló A/S (AKBLF) Shareholder/Analyst Call Transcript

seekingalpha.com

Feb 20

ALK-Abelló A/S (AKBLF) Q4 2025 Earnings Call Transcript

globenewswire.com

Feb 13

Invitation to the presentation of ALK's annual report 2025 on Friday, 20 February 2026

ALK (ALKB:DC / OMX: ALK B) will publish its annual report for 2025 in the morning on Friday, 20 February 2026. Later on the same day, the company will host a presentation for investors and analysts at 1:30 p.m.

Company Profile

ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including house dust mite, grass, tree, ragweed, and Japanese cedar. It also provides adrenaline auto-injectors for the treatment of severe allergic reactions; and manufactures products used in the diagnosis of allergies. The company offers GRAZAX, RAGWITEK, RAGWIZAX, MITICURE, ODACTRA, CEDARCURE, and ITULAZAX for the treatment of allergic rhinitis; and ACARIZAX for treating allergic rhinitis and allergic asthma. ALK-Abelló A/S was founded in 1923 and is headquartered in Hørsholm, Denmark.

Sector

Healthcare

Industry

Biotechnology

Employees

2,736

IPO Date

2009-11-16

Beta

0.63

Websitewww.alk.net↗